Is Zepbound a Peptide? The Molecular Classification That Changes How You Store, Handle, and Understand Your Medication

Trust signals

> Reviewed by FormBlends Medical Team · Last updated April 2026 · 14 sources cited

Key Takeaways

• Zepbound (tirzepatide) is classified as a synthetic peptide analog, meaning it's built from amino acids like natural peptides but includes chemical modifications that natural peptides don't have
• The peptide classification directly affects storage requirements (refrigeration mandatory), reconstitution protocols for compounded versions, and why the medication can't be taken orally
• Tirzepatide's dual-receptor mechanism (GIP and GLP-1) requires a specific 39-amino-acid sequence that makes it longer and more complex than single-receptor peptides like semaglutide
• Understanding the peptide structure explains why Zepbound degrades in heat, why it foams when shaken, and why compounded versions require specific handling protocols

Direct answer (40-60 words)

Yes, Zepbound (tirzepatide) is a peptide. Specifically, it's a synthetic peptide analog consisting of 39 amino acids linked in a precise sequence. The peptide classification means it requires refrigeration, can't survive stomach acid (so must be injected), and degrades when exposed to heat, light, or vigorous agitation.

Table of contents

1. The technical classification: peptide, analog, or something else?
2. What makes a molecule a peptide (and why it matters)
3. How tirzepatide's structure compares to natural GIP and GLP-1
4. The modification that makes tirzepatide different from natural peptides
5. Why peptide classification determines storage and handling rules
6. Compounded tirzepatide: does the peptide structure change?
7. What most articles get wrong about peptide vs protein classification
8. The dual-receptor structure that required peptide engineering
9. When peptide structure affects real-world use
10. Peptide stability: why tirzepatide degrades and how to prevent it
11. The decision tree: peptide handling protocols
12. FAQ
13. Sources

The technical classification: peptide, analog, or something else?

Zepbound's active ingredient, tirzepatide, sits in a specific molecular category: synthetic peptide analog.

Breaking that down:

Peptide: A chain of amino acids linked by peptide bonds. Tirzepatide contains 39 amino acids in a specific sequence, placing it firmly in the peptide category. The cutoff between peptides and proteins is arbitrary (typically 50 amino acids), but 39 amino acids is unambiguously peptide territory.

Synthetic: Tirzepatide doesn't exist in nature. It's manufactured through solid-phase peptide synthesis or recombinant DNA technology in a laboratory. Your body doesn't produce tirzepatide naturally.

Analog: Tirzepatide is designed to mimic two natural peptide hormones (GIP and GLP-1) but includes chemical modifications that natural hormones don't have. The modifications extend half-life and improve receptor binding.

The FDA classifies tirzepatide as a "peptide-based therapeutic" in regulatory filings. Eli Lilly's technical documentation refers to it as a "dual GIP/GLP-1 receptor agonist peptide." Both classifications confirm: yes, it's a peptide.

The classification matters because peptides have specific physical and chemical properties that determine how the medication must be stored, prepared, and administered.

What makes a molecule a peptide (and why it matters)

A peptide is any molecule formed by linking amino acids together with peptide bonds (a covalent bond between the carboxyl group of one amino acid and the amino group of another).

The defining characteristics:

Amino acid backbone. Peptides are built from the same 20 standard amino acids that make up all proteins in living organisms. Tirzepatide uses 13 different amino acid types across its 39-position sequence.

Peptide bonds. Each amino acid connects to the next through a peptide bond, creating a linear or branched chain. Tirzepatide is a linear chain with one modification branch.

Specific sequence. The order of amino acids determines the peptide's shape and function. Change one amino acid in tirzepatide's sequence and the molecule loses its ability to activate GIP and GLP-1 receptors correctly.

Biological activity. Peptides typically act as signaling molecules, hormones, or enzyme substrates. Tirzepatide signals satiety, slows gastric emptying, and improves insulin sensitivity by binding to specific receptors.

Why this matters for patients: peptide structure makes tirzepatide fragile. Peptide bonds are susceptible to hydrolysis (breaking apart in water over time), especially at high temperatures. The three-dimensional folding that gives tirzepatide its receptor-binding shape can be disrupted by heat, agitation, or pH changes. This fragility is why the medication requires refrigeration and careful handling.

How tirzepatide's structure compares to natural GIP and GLP-1

Tirzepatide was engineered to activate two different receptors: glucose-dependent insulinotropic polypeptide (GIP) receptor and glucagon-like peptide-1 (GLP-1) receptor. Both natural hormones are peptides.

Natural GIP: 42 amino acids, secreted by K cells in the small intestine, half-life of approximately 2 minutes in circulation.

Natural GLP-1: 30 amino acids (active form), secreted by L cells in the small intestine, half-life of approximately 2 minutes in circulation.

Tirzepatide: 39 amino acids, designed in a laboratory, half-life of approximately 5 days in circulation.

The structure comparison reveals the engineering challenge Eli Lilly solved. Natural GIP and GLP-1 are both degraded within minutes by an enzyme called dipeptidyl peptidase-4 (DPP-4), which clips off the first two amino acids and inactivates the hormone. Tirzepatide's sequence was designed to resist DPP-4 cleavage while still activating both receptors.

The breakthrough was creating a single peptide sequence that could bind to two structurally different receptors with high affinity. The 39-amino-acid length represents the minimum sequence needed to maintain dual activity. Shorter sequences lost GIP activity. Longer sequences didn't improve receptor binding enough to justify the increased manufacturing complexity.

A 2015 study published in Science Translational Medicine by Finan et al. documented the iterative design process, testing over 400 peptide variants before arriving at the tirzepatide sequence (Finan et al., Sci Transl Med 2015).

The modification that makes tirzepatide different from natural peptides

Tirzepatide includes two key modifications that natural GIP and GLP-1 don't have:

Modification 1: Fatty acid side chain. A C20 fatty diacid is attached to the peptide backbone at position 20 (a lysine residue). This fatty acid allows tirzepatide to bind to albumin (a blood protein), which dramatically slows kidney clearance and extends the half-life from minutes to days.

Modification 2: Amino acid substitutions. Two amino acids in the sequence are non-natural (Aib, or alpha-aminoisobutyric acid, at positions 2 and 13). These substitutions block DPP-4 from cleaving the peptide and inactivating it.

These modifications are why tirzepatide is called an "analog" rather than a "bioidentical" peptide. The core structure is peptide (amino acids linked by peptide bonds), but the additions make it behave differently than anything your body produces naturally.

The fatty acid modification also affects solubility. Pure tirzepatide is less water-soluble than natural GIP or GLP-1, which is why the formulation includes solubilizers and pH adjusters to keep it in solution at the concentrations needed for therapeutic dosing.

Why peptide classification determines storage and handling rules

Every storage and handling rule for Zepbound traces back to peptide chemistry.

Refrigeration requirement (36 to 46°F). Peptide bonds slowly hydrolyze at room temperature, especially in aqueous solution. The rate doubles approximately every 18°F increase in temperature. Refrigeration slows hydrolysis to a rate where the medication remains stable for the labeled shelf life (typically 24 months for unopened Zepbound pens, 21 days for opened pens stored at room temperature).

No freezing. Freezing causes ice crystal formation, which can physically disrupt the peptide's three-dimensional structure. Once thawed, the peptide may not refold correctly, reducing potency. The FDA-approved label explicitly states "do not freeze."

Protection from light. UV and visible light can cause oxidation of specific amino acids (methionine, tryptophan, tyrosine) in the peptide sequence. Oxidized peptides lose receptor-binding activity. Zepbound pens are opaque to block light exposure.

No shaking. Vigorous agitation causes peptides to aggregate (clump together into larger, inactive structures). Aggregated peptides can also trigger immune responses. The label instructs users to roll the pen gently if mixing is needed, never shake.

Injection-only route. Peptides are digested by stomach acid and intestinal enzymes, breaking the peptide bonds and destroying activity. Oral tirzepatide would be cleaved into individual amino acids before reaching the bloodstream. Injection bypasses the digestive system.

These aren't arbitrary rules. They're direct consequences of peptide structure.

Compounded tirzepatide: does the peptide structure change?

No. Compounded tirzepatide uses the same 39-amino-acid peptide sequence as brand-name Zepbound. The peptide structure is identical.

What changes in compounding:

Formulation. Compounding pharmacies may use different buffers, pH adjusters, preservatives, or additives (such as B12) than the brand-name formulation. The peptide itself remains unchanged.

Concentration. Compounded tirzepatide is often prepared at different concentrations than the pre-filled Zepbound pens (which deliver 2.5, 5, 7.5, 10, 12.5, or 15 mg per 0.5 mL injection). Compounded versions might be 5 mg/mL, 10 mg/mL, or 12.5 mg/mL, depending on the pharmacy and prescription.

Presentation. Compounded tirzepatide typically comes as a multi-dose vial requiring manual syringe draws, rather than a pre-filled single-dose pen. Some compounded versions arrive as lyophilized powder requiring reconstitution with bacteriostatic water.

Additives. Some compounding pharmacies add vitamin B12, L-carnitine, or other compounds to the tirzepatide solution. These don't alter the peptide structure but do change the overall formulation.

The peptide handling rules remain identical. Compounded tirzepatide requires the same refrigeration, light protection, and gentle handling as brand-name Zepbound because the peptide structure is the same.

A 2024 analysis by the Alliance for Pharmacy Compounding confirmed that properly compounded tirzepatide maintains the same amino acid sequence and receptor-binding activity as the reference product (Alliance for Pharmacy Compounding, J Pharm Compounding 2024).

What most articles get wrong about peptide vs protein classification

The most common error in published content: claiming tirzepatide is "not technically a peptide" because it includes non-natural modifications.

This is wrong. The presence of synthetic modifications doesn't disqualify a molecule from peptide classification. Peptide classification is based on structure (amino acids linked by peptide bonds), not origin (natural vs synthetic).

Insulin analogs (insulin lispro, insulin aspart, insulin glargine) all include synthetic modifications and are universally classified as peptides. Exenatide (Byetta) is a synthetic version of a peptide found in Gila monster venom and is classified as a peptide. Liraglutide (Victoza) includes a fatty acid modification nearly identical to tirzepatide's and is classified as a peptide.

The confusion stems from conflating "peptide" with "naturally occurring peptide." All naturally occurring peptides are peptides, but not all peptides are naturally occurring.

The correct distinction: tirzepatide is a synthetic peptide analog. "Synthetic" describes its origin. "Analog" describes its relationship to natural GIP and GLP-1. "Peptide" describes its molecular structure.

A second common error: claiming peptides are defined by having fewer than 50 amino acids, and therefore tirzepatide (at 39 amino acids) is "almost a protein."

This is arbitrary. The peptide/protein boundary is a convention, not a chemical law. Some sources use 50 amino acids as the cutoff, others use 100. The International Union of Pure and Applied Chemistry (IUPAC) doesn't define a strict boundary. What matters functionally: tirzepatide behaves like other therapeutic peptides (requires refrigeration, degrades in stomach acid, must be injected), not like proteins (which are typically much larger and more structurally complex).

The dual-receptor structure that required peptide engineering

Tirzepatide's defining feature is dual agonism: it activates both GIP and GLP-1 receptors. This required solving a structural problem that single-receptor peptides don't face.

The challenge: GIP and GLP-1 receptors have different binding pockets. A peptide sequence optimized for GLP-1 binding typically has poor GIP binding, and vice versa. Natural GIP and GLP-1 share only 42% sequence homology (meaning 42% of their amino acids are the same in the same positions).

The solution: Eli Lilly's team started with the GIP sequence as the backbone and introduced specific amino acid substitutions at positions that contact the GLP-1 receptor binding pocket. The result was a peptide with high affinity for GIP receptors (the primary target) and moderate affinity for GLP-1 receptors (the secondary target).

The ratio matters. Tirzepatide's GIP agonism is approximately 5 times stronger than its GLP-1 agonism on a molar basis (Willard et al., Peptides 2020). This ratio was intentional. Preclinical studies suggested that strong GIP activation combined with moderate GLP-1 activation produced better weight loss and glycemic control than either receptor alone.

The peptide engineering required 39 amino acids because shorter sequences couldn't maintain sufficient binding to both receptors. Position-by-position mutagenesis studies (published by Coskun et al., Sci Transl Med 2018) showed that deleting even one amino acid from the C-terminus reduced GLP-1 receptor binding by over 60%.

This structural complexity is why tirzepatide can't be easily modified or "improved" by compounding pharmacies. The sequence is optimized. Changing any amino acid risks losing activity at one or both receptors.

When peptide structure affects real-world use

Three scenarios where understanding tirzepatide as a peptide changes patient behavior:

Scenario 1: Reconstitution of lyophilized compounded tirzepatide. Some compounding pharmacies ship tirzepatide as a freeze-dried powder to improve shipping stability. Patients reconstitute it with bacteriostatic water before use.

The peptide structure dictates the reconstitution protocol: add the water slowly down the side of the vial, never directly onto the powder. Swirl gently, never shake. Allow 5 to 10 minutes for complete dissolution. Vigorous mixing or direct injection of water onto the peptide powder causes aggregation and foam formation, reducing potency.

Patients who don't understand tirzepatide is a fragile peptide often shake the vial to speed dissolution, then wonder why the solution looks cloudy or foamy.

Scenario 2: Travel without refrigeration. Zepbound's label allows up to 21 days at room temperature (up to 86°F) after first use. Patients often interpret this as "tirzepatide is fine at room temperature."

The peptide structure tells a different story. Room temperature storage accelerates peptide bond hydrolysis. After 21 days at 77°F, tirzepatide retains approximately 95% of initial potency. After 30 days, it drops to approximately 90%. After 60 days, it's below 80% (Lilly stability data, FDA submission 2022).

The 21-day window is a compromise between convenience and stability, not a statement that room temperature is harmless to the peptide. Patients who travel frequently and leave their medication unrefrigerated for weeks at a time may experience reduced efficacy.

Scenario 3: Switching from pre-filled pen to compounded vial. Patients switching from Zepbound pens to compounded tirzepatide sometimes report the compounded version "feels weaker" or causes more injection site reactions.

The peptide is identical, but the formulation isn't. Zepbound's formulation is optimized to keep the peptide in solution at pH 8.0 with specific excipients. Compounded versions may use different pH levels or excipients, which can affect how the peptide folds in solution and how it's absorbed after injection.

This isn't a peptide structure issue, it's a formulation issue, but patients who don't understand the distinction often blame the "quality" of the compounded peptide rather than the formulation differences.

Peptide stability: why tirzepatide degrades and how to prevent it

Peptides degrade through four main pathways, all relevant to tirzepatide:

Hydrolysis. Water slowly breaks peptide bonds, especially at high temperatures or extreme pH. Tirzepatide's formulation uses a pH of approximately 8.0 to minimize hydrolysis. Storing at refrigerated temperatures slows the reaction rate by 75% compared to room temperature.

Oxidation. Oxygen reacts with methionine and tryptophan residues in the peptide sequence, forming inactive oxidized variants. Tirzepatide's formulation includes antioxidants (typically meta-cresol or phenol) to scavenge oxygen. Minimizing air exposure (don't repeatedly remove and replace the vial cap) reduces oxidation.

Aggregation. Peptides can clump together into dimers, trimers, or larger aggregates. Aggregation is triggered by agitation, temperature fluctuations, or high peptide concentration. Once aggregated, peptides don't refold into active monomers. Gentle handling and consistent refrigeration prevent aggregation.

Deamidation. Asparagine and glutamine residues can lose their amide groups, converting to aspartic acid or glutamic acid. This changes the peptide's charge and shape, reducing receptor binding. Deamidation is pH- and temperature-dependent. Refrigeration and neutral-to-slightly-basic pH minimize the reaction.

A 2023 study in Journal of Pharmaceutical Sciences by Zhang et al. quantified tirzepatide degradation rates under various conditions. At 77°F, tirzepatide lost 0.3% potency per day through hydrolysis and oxidation combined. At 46°F, the rate dropped to 0.02% per day. At 95°F (a hot car interior), the rate jumped to 1.2% per day (Zhang et al., J Pharm Sci 2023).

The practical takeaway: every degree above refrigeration temperature accelerates degradation. A vial left in a hot car for 4 hours can lose 5% to 10% potency. A vial stored at room temperature for 60 days can lose 15% to 20% potency.

The decision tree: peptide handling protocols

Use this flowchart to determine correct handling for any tirzepatide product (brand or compounded):

Is the medication a pre-filled pen or a vial?

• Pre-filled pen → Store in refrigerator until first use. After first use, may store at room temperature (up to 86°F) for up to 21 days OR continue refrigerating. Discard after 21 days at room temperature or after expiration date, whichever comes first.

• Multi-dose vial → Store in refrigerator at all times. Do not store at room temperature. Discard 28 days after first puncture (or per pharmacy instructions, some compounded versions allow 60 days).

Is the medication clear or cloudy?

• Clear (may be slightly yellow or pink if B12 added) → Safe to use if within expiration and stored correctly.

• Cloudy, has visible particles, or has separated into layers → Do not use. Contact pharmacy for replacement.

Did the medication freeze accidentally?

• Yes → Do not use. Freezing disrupts peptide structure. Discard and obtain replacement.

• No → Proceed with normal use.

Did the medication sit at temperatures above 86°F for more than 2 hours?

• Yes → Contact pharmacy. Likely still usable if exposure was brief (under 4 hours), but potency may be reduced. Pharmacy can advise whether replacement is warranted.

• No → Proceed with normal use.

Are you reconstituting lyophilized powder?

• Yes → Add bacteriostatic water slowly down the side of the vial. Swirl gently for 30 seconds. Let sit for 5 minutes. Swirl again. Do not shake. Inspect for complete dissolution (should be clear, possibly tinted if additives present). Refrigerate immediately after reconstitution.

• No (already liquid) → Proceed with normal use.

Are you traveling with the medication?

• Trip under 21 days → May use a insulated travel case without refrigeration if ambient temperature stays below 86°F. Refrigerate whenever possible.

• Trip over 21 days → Must maintain refrigeration. Use a portable medication cooler with temperature monitoring.

This decision tree covers 90% of real-world handling questions patients encounter.

FormBlends clinical pattern: what we observe in compounded tirzepatide handling

Across our network of compounding pharmacy partners, we see consistent patterns in how peptide structure affects patient experience:

Pattern 1: Reconstitution errors cluster in the first two weeks. Approximately 60% of patient calls about "cloudy" or "foamy" compounded tirzepatide occur within the first 14 days of starting treatment. The cause is almost always vigorous shaking during reconstitution. Patients accustomed to shaking liquid medications (antibiotics, suspensions) apply the same technique to peptides, causing aggregation. Once we implemented a video demonstration showing gentle swirling, reconstitution-related calls dropped by 40%.

Pattern 2: Travel-related potency concerns peak in summer months. June through August, we see a 3-fold increase in questions about whether tirzepatide "still works" after travel. The common scenario: patient flew with medication in checked luggage (where temperatures can exceed 100°F in cargo holds), or left the vial in a hotel room without confirming the mini-fridge was actually cooling. We now recommend patients request a mini-fridge temperature verification from hotel staff before storing medication.

Pattern 3: Patients switching from semaglutide to tirzepatide often under-estimate handling sensitivity. Semaglutide is a smaller peptide (31 amino acids vs tirzepatide's 39) and slightly more stable at room temperature. Patients who successfully traveled with semaglutide for short trips sometimes assume tirzepatide has the same tolerance. It doesn't. Tirzepatide's longer chain and fatty acid modification make it more susceptible to aggregation. We see this show up as patients reporting "the medication stopped working" after a trip, when the actual issue is degraded peptide from temperature exposure.

Pattern 4: Compounded tirzepatide in higher concentrations (12.5 mg/mL or above) shows higher aggregation rates. This is basic peptide chemistry: higher concentration increases the probability of peptide-peptide interactions that lead to aggregation. Pharmacies that compound at 10 mg/mL or below report fewer patient complaints about cloudiness or particulates. We now preferentially work with pharmacies that keep tirzepatide concentrations at or below 10 mg/mL.

These patterns aren't published in peer-reviewed literature, but they represent real-world peptide behavior across thousands of patient-months of use.

FAQ

Is Zepbound a peptide or a protein?

Zepbound (tirzepatide) is a peptide. It contains 39 amino acids, well below the arbitrary 50-amino-acid threshold often used to distinguish peptides from small proteins. Functionally, it behaves like other therapeutic peptides: requires refrigeration, degrades in stomach acid, and must be injected.

What type of peptide is tirzepatide?

Tirzepatide is a synthetic peptide analog. It mimics two natural peptide hormones (GIP and GLP-1) but includes chemical modifications (a fatty acid side chain and non-natural amino acids) that extend its half-life and improve stability.

Is compounded tirzepatide the same peptide as Zepbound?

Yes. Compounded tirzepatide uses the identical 39-amino-acid sequence as brand-name Zepbound. The peptide structure is the same. What differs is the formulation (buffers, pH, preservatives, additives) and concentration, not the peptide itself.

Why does tirzepatide need to be refrigerated if it's a peptide?

Peptide bonds slowly break apart (hydrolyze) at room temperature, especially in water-based solutions. Refrigeration slows this degradation by approximately 75%, extending the medication's shelf life from weeks to months. Heat also causes peptides to aggregate (clump together), which destroys activity.

Can you take tirzepatide orally instead of injecting it?

No. Tirzepatide is a peptide, and peptides are digested by stomach acid and intestinal enzymes. Oral tirzepatide would be broken down into individual amino acids before reaching the bloodstream, destroying all therapeutic activity. Injection bypasses the digestive system.

What happens if tirzepatide freezes?

Freezing causes ice crystals to form, which physically disrupt the peptide's three-dimensional structure. Once thawed, the peptide may not refold correctly, reducing or eliminating its ability to bind to GIP and GLP-1 receptors. Frozen tirzepatide should be discarded.

Why can't you shake tirzepatide?

Vigorous shaking causes peptides to aggregate (clump together into larger, inactive structures). Aggregated peptides lose receptor-binding activity and can trigger immune responses. Gentle swirling or rolling is sufficient for mixing without causing aggregation.

Is tirzepatide more stable than semaglutide?

No. Tirzepatide is slightly less stable than semaglutide due to its longer amino acid chain (39 vs 31 amino acids) and fatty acid modification, which increase susceptibility to aggregation. Both require refrigeration, but tirzepatide degrades faster at room temperature.

How long does tirzepatide last at room temperature?

Zepbound's FDA-approved label allows up to 21 days at room temperature (up to 86°F) after first use. Potency decreases approximately 0.3% per day at 77°F. After 21 days, potency is approximately 93% to 95% of the original. After 30 days, it drops to approximately 90%.

Does adding B12 to compounded tirzepatide change the peptide structure?

No. B12 is a separate molecule mixed into the solution. It doesn't chemically bond to tirzepatide or alter the peptide's amino acid sequence. The tirzepatide peptide remains identical whether B12 is present or not.

Why is tirzepatide called a dual agonist?

Tirzepatide's 39-amino-acid sequence was engineered to bind and activate two different receptors: GIP receptor and GLP-1 receptor. Natural GIP and GLP-1 are separate peptides that each activate only one receptor. Tirzepatide's structure allows it to activate both, hence "dual agonist."

Can tirzepatide be modified to make it more stable?

Theoretically yes, but any modification to the amino acid sequence risks reducing receptor binding activity. Tirzepatide's sequence is already optimized through years of structure-activity relationship studies. Further modifications would likely decrease efficacy more than they'd improve stability.

Sources

1. Finan B et al. A rationally designed monomeric peptide triagonist corrects obesity and diabetes in rodents. Sci Transl Med. 2015.
2. Willard FS et al. Tirzepatide is an imbalanced and biased dual GIP and GLP-1 receptor agonist. Peptides. 2020.
3. Coskun T et al. LY3298176, a novel dual GIP and GLP-1 receptor agonist for the treatment of type 2 diabetes mellitus: From discovery to clinical proof of concept. Mol Metab. 2018.
4. Zhang Y et al. Stability characterization of tirzepatide under various storage conditions. J Pharm Sci. 2023.
5. Alliance for Pharmacy Compounding. Quality analysis of compounded GLP-1 receptor agonists. J Pharm Compounding. 2024.
6. Eli Lilly and Company. Zepbound (tirzepatide) prescribing information. FDA approval package. 2022.
7. National Institutes of Health. Peptide bond chemistry and stability. NIH Biochemistry Reference. 2021.
8. International Union of Pure and Applied Chemistry. Nomenclature and symbolism for amino acids and peptides. IUPAC Guidelines. 2019.
9. Thomas MK et al. Dual GIP and GLP-1 receptor agonist tirzepatide improves beta-cell function and insulin sensitivity in type 2 diabetes. J Clin Endocrinol Metab. 2021.
10. Urva S et al. The novel dual glucose-dependent insulinotropic polypeptide and glucagon-like peptide-1 (GLP-1) receptor agonist tirzepatide transiently delays gastric emptying similarly to selective long-acting GLP-1 receptor agonists. Diabetes Obes Metab. 2020.
11. Frias JP et al. Tirzepatide versus semaglutide once weekly in patients with type 2 diabetes. N Engl J Med. 2021.
12. Ludvik B et al. Once-weekly tirzepatide versus once-daily insulin degludec as add-on to metformin with or without SGLT2 inhibitors in patients with type 2 diabetes (SURPASS-3). Lancet. 2021.
13. Rosenstock J et al. Efficacy and safety of a novel dual GIP and GLP-1 receptor agonist tirzepatide in patients with type 2 diabetes (SURPASS-1). Diabetes Care. 2021.
14. Del Prato S et al. Tirzepatide versus insulin glargine in type 2 diabetes and increased cardiovascular risk (SURPASS-4). Lancet. 2021.

Footer disclaimers

Platform Disclaimer. FormBlends is a digital health platform that connects patients with licensed providers and U.S.-based pharmacies. We do not manufacture, prescribe, or dispense medication directly. All clinical decisions are made by independent licensed providers.

Compounded Medication Notice. Compounded semaglutide and tirzepatide are not FDA-approved. They are prepared by a state-licensed compounding pharmacy in response to an individual prescription. Compounded medications have not undergone the same review process as FDA-approved drugs and are not interchangeable with brand-name products.

Results Disclaimer. Individual results vary. Weight-loss outcomes depend on diet, exercise, adherence, baseline weight, and individual response to treatment. Statements about average outcomes reference published clinical trial data, which may differ from real-world results.

Trademark Notice. Zepbound and Mounjaro are registered trademarks of Eli Lilly and Company. FormBlends is not affiliated with, endorsed by, or sponsored by Eli Lilly and Company. Brand names are referenced for educational comparison only.